• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类3D卵巢癌模型揭示影响CAR T细胞活性的恶性细胞内在和外在因素。

Human 3D Ovarian Cancer Models Reveal Malignant Cell-Intrinsic and -Extrinsic Factors That Influence CAR T-cell Activity.

作者信息

Joy Joash D, Malacrida Beatrice, Laforêts Florian, Kotantaki Panoraia, Maniati Eleni, Manchanda Ranjit, Annibaldi Alessandro, Hopkins Sarah, Garrobo-Calleja Ianire, Gautrot Julien, Balkwill Frances R

机构信息

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Wolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, London, United Kingdom.

出版信息

Cancer Res. 2024 Aug 1;84(15):2432-2449. doi: 10.1158/0008-5472.CAN-23-3007.

DOI:10.1158/0008-5472.CAN-23-3007
PMID:38819641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292204/
Abstract

In vitro preclinical testing of chimeric antigen receptor (CAR) T cells is mostly carried out in monolayer cell cultures. However, alternative strategies are needed to take into account the complexity and the effects of the tumor microenvironment. Here, we describe the modulation of CAR T-cell activity by malignant cells and fibroblasts in human three-dimensional (3D) in vitro cell models of increasing complexity. In models combining mucin-1 (MUC1) and TnMUC1 CAR T cells with human high-grade serous ovarian cancer cell spheroids, malignant cell-intrinsic resistance to CAR T-cell killing was due to defective death receptor signaling involving TNFα. Adding primary human fibroblasts to spheroids unexpectedly increased the ability of CAR T cells to kill resistant malignant cells as CCL2 produced by fibroblasts activated CCR2/4+ CAR T cells. However, culturing malignant cells and fibroblasts in collagen gels engendered production of a dense extracellular matrix that impeded CAR T-cell activity in a TGFβ-dependent manner. A vascularized microfluidic device was developed that allowed CAR T cells to flow through the vessels and penetrate the gels in a more physiological way, killing malignant cells in a TNFα-dependent manner. Complex 3D human cell models may provide an efficient way of screening multiple cytotoxic human immune cell constructs while also enabling evaluation of mechanisms of resistance involving cell-cell and cell-matrix interactions, thus accelerating preclinical research on cytotoxic immune cell therapies in solid tumors. Significance: Three-dimensional in vitro models of increasing complexity uncover mechanisms of resistance to CAR T cells in solid tumors, which could help accelerate development of improved CAR T-cell constructs.

摘要

嵌合抗原受体(CAR)T细胞的体外临床前测试大多在单层细胞培养中进行。然而,需要采用其他策略来考虑肿瘤微环境的复杂性及其影响。在此,我们描述了在复杂性不断增加的人三维(3D)体外细胞模型中,恶性细胞和成纤维细胞对CAR T细胞活性的调节作用。在将粘蛋白-1(MUC1)和TnMUC1 CAR T细胞与人类高级别浆液性卵巢癌细胞球体相结合的模型中,恶性细胞对CAR T细胞杀伤的内在抗性归因于涉及肿瘤坏死因子α(TNFα)的死亡受体信号传导缺陷。将原代人成纤维细胞添加到球体中意外地增强了CAR T细胞杀伤抗性恶性细胞的能力,因为成纤维细胞产生的趋化因子配体2(CCL2)激活了CCR2/4+ CAR T细胞。然而,在胶原凝胶中培养恶性细胞和成纤维细胞会产生致密的细胞外基质,以转化生长因子β(TGFβ)依赖的方式阻碍CAR T细胞的活性。我们开发了一种血管化微流控装置,使CAR T细胞能够以更符合生理的方式流经血管并穿透凝胶,以TNFα依赖的方式杀伤恶性细胞。复杂的3D人类细胞模型可能提供一种有效的方法来筛选多种细胞毒性人类免疫细胞构建体,同时还能评估涉及细胞间和细胞与基质相互作用的抗性机制,从而加速实体瘤细胞毒性免疫细胞疗法的临床前研究。意义:复杂性不断增加的三维体外模型揭示了实体瘤对CAR T细胞的抗性机制,这有助于加速改进型CAR T细胞构建体的开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/98b0cc8c10f2/can-23-3007_f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/4df85f5c76f9/can-23-3007_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/4e7014e3bafc/can-23-3007_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/9cf76fd6ce69/can-23-3007_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/dc40278ef641/can-23-3007_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/7937703f6357/can-23-3007_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/3fb7dbd4d1e7/can-23-3007_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/98b0cc8c10f2/can-23-3007_f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/4df85f5c76f9/can-23-3007_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/4e7014e3bafc/can-23-3007_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/9cf76fd6ce69/can-23-3007_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/dc40278ef641/can-23-3007_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/7937703f6357/can-23-3007_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/3fb7dbd4d1e7/can-23-3007_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb77/11292204/98b0cc8c10f2/can-23-3007_f7.jpg

相似文献

1
Human 3D Ovarian Cancer Models Reveal Malignant Cell-Intrinsic and -Extrinsic Factors That Influence CAR T-cell Activity.人类3D卵巢癌模型揭示影响CAR T细胞活性的恶性细胞内在和外在因素。
Cancer Res. 2024 Aug 1;84(15):2432-2449. doi: 10.1158/0008-5472.CAN-23-3007.
2
Effective Targeting of TAG72 Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.通过区域递送 CAR 工程化 T 细胞靶向 TAG72 腹膜卵巢肿瘤。
Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018.
3
Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.腺苷 2A 受体的破坏可提高抗间皮素 CAR T 细胞的抗肿瘤功能,无论是在体外还是体内。
Exp Cell Res. 2021 Dec 1;409(1):112886. doi: 10.1016/j.yexcr.2021.112886. Epub 2021 Oct 19.
4
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.双 CAR-T 靶向 PDL1 和 MUC16 抗原对小鼠卵巢癌细胞的治疗效果。
BMC Cancer. 2020 Jul 20;20(1):678. doi: 10.1186/s12885-020-07180-x.
5
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.克服阻碍 CAR T 细胞有效浸润实体瘤的障碍。
J Leukoc Biol. 2020 Oct;108(4):1067-1079. doi: 10.1002/JLB.1MR0520-746R. Epub 2020 Jul 3.
6
Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.卵巢癌中针对肿瘤抗原 5T4 的嵌合抗原受体 T 细胞疗法的临床前评估。
J Immunother. 2018 Apr;41(3):130-140. doi: 10.1097/CJI.0000000000000203.
7
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.ROR1-CAR T 细胞在先进的微生理 3D 肿瘤模型中对肺癌和乳腺癌有效。
JCI Insight. 2019 Sep 19;4(18):126345. doi: 10.1172/jci.insight.126345.
8
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.嵌合抗原受体 T 细胞直击肿瘤微环境:克服肿瘤逃逸的策略。
Front Immunol. 2020 Jun 17;11:1109. doi: 10.3389/fimmu.2020.01109. eCollection 2020.
9
Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.曲妥珠单抗衍生的 HER2 特异性嵌合抗原受体用于治疗曲妥珠单抗耐药的乳腺癌:CAR T 细胞可穿透并清除抗体不可及的肿瘤。
Cancer Lett. 2020 Aug 1;484:1-8. doi: 10.1016/j.canlet.2020.04.008. Epub 2020 Apr 11.
10
High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.高通量方法使用图像细胞术分析 CAR-T 细胞在 3D 肿瘤球体模型中的细胞毒性。
SLAS Discov. 2023 Apr;28(3):65-72. doi: 10.1016/j.slasd.2023.01.008. Epub 2023 Feb 8.

引用本文的文献

1
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors.从球体到类器官:实体瘤中CAR-T细胞疗法研究的下一代模型
Front Immunol. 2025 Jul 11;16:1626369. doi: 10.3389/fimmu.2025.1626369. eCollection 2025.
2
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives.揭示高级别浆液性卵巢癌(HGSOC)的耐药途径:最新进展与未来展望
Front Immunol. 2025 Apr 30;16:1556377. doi: 10.3389/fimmu.2025.1556377. eCollection 2025.
3
Tumor-Associated Extracellular Matrix Obstacles for CAR-T Cell Therapy: Approaches to Overcoming.

本文引用的文献

1
3D cancer models: One step closer to human studies.3D 癌症模型:离人体研究更近一步。
Front Immunol. 2023 Apr 11;14:1175503. doi: 10.3389/fimmu.2023.1175503. eCollection 2023.
2
Semi-supervised analysis of myeloid and T cell behavior in ovarian tumor slices reveals changes in cell motility after treatments.对卵巢肿瘤切片中髓样细胞和T细胞行为的半监督分析揭示了治疗后细胞运动性的变化。
iScience. 2023 Mar 29;26(4):106514. doi: 10.1016/j.isci.2023.106514. eCollection 2023 Apr 21.
3
FDA Modernization Act 2.0 allows for alternatives to animal testing.
嵌合抗原受体T细胞疗法面临的肿瘤相关细胞外基质障碍:克服方法
Curr Oncol. 2025 Jan 30;32(2):79. doi: 10.3390/curroncol32020079.
4
CD8 T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy.肿瘤微环境中 CD8 T 细胞耗竭及其调控机制:免疫治疗成功的关键。
Front Immunol. 2024 Sep 20;15:1476904. doi: 10.3389/fimmu.2024.1476904. eCollection 2024.
《美国食品药品监督管理局现代化法案2.0》允许采用动物试验的替代方法。
Artif Organs. 2023 Mar;47(3):449-450. doi: 10.1111/aor.14503. Epub 2023 Feb 10.
4
New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay.微流控芯片分析中促进肿瘤球体血管生成的新策略。
Adv Healthc Mater. 2023 Jun;12(14):e2201784. doi: 10.1002/adhm.202201784. Epub 2022 Nov 15.
5
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.Meflin 阳性的癌相关成纤维细胞增强肿瘤对免疫检查点阻断的反应。
Life Sci Alliance. 2022 Mar 2;5(6). doi: 10.26508/lsa.202101230. Print 2022 Jun.
6
Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers.提高嵌合抗原受体T细胞在实体癌中疗效的策略
Cancers (Basel). 2022 Jan 23;14(3):571. doi: 10.3390/cancers14030571.
7
3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages.3D 细胞培养系统:肿瘤应用、优势和劣势。
Int J Mol Sci. 2021 Nov 11;22(22):12200. doi: 10.3390/ijms222212200.
8
GD2 CAR T cells against human glioblastoma.针对人类胶质母细胞瘤的GD2嵌合抗原受体T细胞
NPJ Precis Oncol. 2021 Oct 27;5(1):93. doi: 10.1038/s41698-021-00233-9.
9
A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.可重现生物打印的 3D 肿瘤模型可作为 CAR T 细胞治疗优化的预选工具。
Front Immunol. 2021 Jun 29;12:689697. doi: 10.3389/fimmu.2021.689697. eCollection 2021.
10
A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion.一种人类多细胞模型展示了血小板如何驱动病变细胞外基质的产生和组织侵袭。
iScience. 2021 May 29;24(6):102676. doi: 10.1016/j.isci.2021.102676. eCollection 2021 Jun 25.